REGENXBIO Inc.

NasdaqGS:RGNX 株式レポート

時価総額：US$477.1m

REGENXBIO マネジメント

マネジメント 基準チェック /24

REGENXBIOの CEO はCurran Simpsonで、 Jul2024年に任命され、 の在任期間は 1 年未満です。 の年間総報酬は$ 2.95Mで、 17.4%給与と82.6%のボーナス（会社の株式とオプションを含む）で構成されています。 は、会社の株式の0.031%を直接所有しており、その価値は$ 147.91K 。経営陣と取締役会の平均在任期間はそれぞれ5.9年と7.4年です。

主要情報

Curran Simpson

最高経営責任者

US$3.0m

報酬総額

CEO給与比率17.4%
CEO在任期間less than a year
CEOの所有権0.03%
経営陣の平均在職期間5.9yrs
取締役会の平均在任期間7.4yrs

経営陣の近況

Recent updates

REGENXBIO: With Additional MPS II Data, Program Advancement Remains On Track

Oct 31

Does REGENXBIO (NASDAQ:RGNX) Have A Healthy Balance Sheet?

Sep 12
Does REGENXBIO (NASDAQ:RGNX) Have A Healthy Balance Sheet?

Regenxbio: RGX-121 Could Achieve A First For Rare Neurodegenerative Disorder

Aug 06

REGENXBIO Inc. (NASDAQ:RGNX) Second-Quarter Results: Here's What Analysts Are Forecasting For This Year

Aug 04
REGENXBIO Inc. (NASDAQ:RGNX) Second-Quarter Results: Here's What Analysts Are Forecasting For This Year

Revenues Working Against REGENXBIO Inc.'s (NASDAQ:RGNX) Share Price

Jul 26
Revenues Working Against REGENXBIO Inc.'s (NASDAQ:RGNX) Share Price

Regenxbio: Transforming Gene Therapy With Innovative AAV Treatments, Strong Buy

Jun 11

REGENXBIO Inc. (NASDAQ:RGNX) Analysts Are Cutting Their Estimates: Here's What You Need To Know

May 11
REGENXBIO Inc. (NASDAQ:RGNX) Analysts Are Cutting Their Estimates: Here's What You Need To Know

REGENXBIO Inc. (NASDAQ:RGNX) Not Doing Enough For Some Investors As Its Shares Slump 26%

Apr 25
REGENXBIO Inc. (NASDAQ:RGNX) Not Doing Enough For Some Investors As Its Shares Slump 26%

Regenxbio: DMD Program Lends Additional Credibility To NAV Technology Platform

Mar 11

Analysts Just Slashed Their REGENXBIO Inc. (NASDAQ:RGNX) EPS Numbers

Mar 07
Analysts Just Slashed Their REGENXBIO Inc. (NASDAQ:RGNX) EPS Numbers

Improved Revenues Required Before REGENXBIO Inc. (NASDAQ:RGNX) Stock's 75% Jump Looks Justified

Mar 05
Improved Revenues Required Before REGENXBIO Inc. (NASDAQ:RGNX) Stock's 75% Jump Looks Justified

Earnings Update: REGENXBIO Inc. (NASDAQ:RGNX) Just Reported Its Yearly Results And Analysts Are Updating Their Forecasts

Mar 02
Earnings Update: REGENXBIO Inc. (NASDAQ:RGNX) Just Reported Its Yearly Results And Analysts Are Updating Their Forecasts

Regenxbio: Robust Data, Decent Cash, Never Ending Trials, Buying At Dips

Jan 19

There's No Escaping REGENXBIO Inc.'s (NASDAQ:RGNX) Muted Revenues

Dec 21
There's No Escaping REGENXBIO Inc.'s (NASDAQ:RGNX) Muted Revenues

We Think REGENXBIO (NASDAQ:RGNX) Needs To Drive Business Growth Carefully

Nov 09
We Think REGENXBIO (NASDAQ:RGNX) Needs To Drive Business Growth Carefully

Will REGENXBIO (NASDAQ:RGNX) Spend Its Cash Wisely?

Aug 08
Will REGENXBIO (NASDAQ:RGNX) Spend Its Cash Wisely?

REGENXBIO Inc. (NASDAQ:RGNX) Analysts Just Trimmed Their Revenue Forecasts By 12%

May 11
REGENXBIO Inc. (NASDAQ:RGNX) Analysts Just Trimmed Their Revenue Forecasts By 12%

Here's Why We're Watching REGENXBIO's (NASDAQ:RGNX) Cash Burn Situation

May 08
Here's Why We're Watching REGENXBIO's (NASDAQ:RGNX) Cash Burn Situation

Analysts Are More Bearish On REGENXBIO Inc. (NASDAQ:RGNX) Than They Used To Be

Mar 05
Analysts Are More Bearish On REGENXBIO Inc. (NASDAQ:RGNX) Than They Used To Be

CEO報酬分析

REGENXBIO の収益と比較して、Curran Simpson の報酬はどのように変化したか？
日付総報酬給与会社業績
Sep 30 2024n/an/a

-US$239m

Jun 30 2024n/an/a

-US$241m

Mar 31 2024n/an/a

-US$260m

Dec 31 2023US$3mUS$513k

-US$263m

Sep 30 2023n/an/a

-US$261m

Jun 30 2023n/an/a

-US$274m

Mar 31 2023n/an/a

-US$270m

Dec 31 2022US$2mUS$475k

-US$280m

Sep 30 2022n/an/a

US$74m

Jun 30 2022n/an/a

US$91m

Mar 31 2022n/an/a

US$101m

Dec 31 2021US$3mUS$448k

US$128m

Sep 30 2021n/an/a

-US$212m

Jun 30 2021n/an/a

-US$145m

Mar 31 2021n/an/a

-US$121m

Dec 31 2020US$2mUS$428k

-US$111m

Sep 30 2020n/an/a

-US$91m

Jun 30 2020n/an/a

-US$135m

Mar 31 2020n/an/a

-US$103m

Dec 31 2019US$2mUS$382k

-US$95m

Sep 30 2019n/an/a

-US$64m

Jun 30 2019n/an/a

-US$49m

Mar 31 2019n/an/a

-US$37m

Dec 31 2018US$2mUS$371k

US$100m

Sep 30 2018n/an/a

US$80m

Jun 30 2018n/an/a

US$78m

Mar 31 2018n/an/a

US$53m

Dec 31 2017US$912kUS$361k

-US$73m

報酬と市場: Curranの 総報酬 ($USD 2.95M ) は、 US市場 ($USD 2.24M ) の同規模の企業の平均を上回っています。

報酬と収益: Curranの報酬は増加しましたが、会社は利益を上げていません。

CEO（最高経営責任者

Curran Simpson (62 yo)

less than a year

在職期間

US$2,950,002

報酬

Mr. Curran M. Simpson, M.S., had been the Chief Operating Officer at REGENXBIO Inc. since January 2023 until July 01, 2024 and served as its Executive Vice President until July 01, 2024 and serves as its P...

リーダーシップ・チーム

名称ポジション在職期間報酬所有権
Curran Simpson
Presidentless than a yearUS$2.95m0.031%
$ 147.9k
Olivier Danos
Executive VP & Chief Scientific Officer7.7yrsUS$2.99m0.061%
$ 289.4k
Vittal Vasista
Advisorless than a yearUS$2.62m0.38%
$ 1.8m
Stephen Pakola
Executive VP & Chief Medical Officer5.6yrsUS$3.31m0%
$ 0
Mitchell Chan
Executive VP & CFOless than a yearデータなしデータなし
Patrick Christmas
Executive VP & Chief Legal Officer8.3yrsUS$3.44m0.046%
$ 219.5k
Shiva Fritsch
Chief Communications & People Officer7.1yrsデータなしデータなし
Ram Palanki
Executive VP of Commercial Strategy & Operations6.3yrsデータなしデータなし

5.9yrs

平均在職期間

55yo

平均年齢

経験豊富な経営陣: RGNXの経営陣は経験豊富で経験豊富です（平均在職期間は5.9年）。

取締役

名称ポジション在職期間報酬所有権
Curran Simpson
Presidentless than a yearUS$2.95m0.031%
$ 147.9k
David Stump
Independent Director9.1yrsUS$339.98k0.0061%
$ 29.0k
George Migausky
Independent Director3.2yrsUS$339.98k0.0061%
$ 29.0k
Argeris Karabelas
Independent Director9.5yrsUS$352.48k0.013%
$ 62.6k
Inder Verma
Member of Scientific Advisorno dataデータなしデータなし
Allan Fox
Director15.8yrsUS$354.98k6.39%
$ 30.5m
Judith Swain
Member of Scientific Advisorno dataデータなしデータなし
Alexandra Glucksmann
Independent Director6.5yrsUS$327.48k0.0061%
$ 29.0k
Daniel Tassé
Lead Independent Director8.3yrsUS$334.98k0.0061%
$ 29.0k
Jean Bennett
Independent Director3.2yrsUS$324.98k0.0061%
$ 29.0k
Kenneth Mills
Chairman15.7yrsUS$5.92m0.63%
$ 3.0m
Jennifer Zachary
Independent Director2.4yrsUS$329.98k0.0040%
$ 19.3k

7.4yrs

平均在職期間

69.5yo

平均年齢

経験豊富なボード: RGNXの 取締役会 は 経験豊富 であると考えられます ( 7.4年の平均在任期間)。